Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.

doi:10.1182/asheducation-2015.1.565

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition.

Hematology. American Society of Hematology. Education Program - 1 Jan 2015

Abla Oussama, Weitzman Sheila

Abstract excerpt

Langerhans cell histiocytosis (LCH) is a clonally derived neoplasm with a highly variable clinical course. Although LCH was once considered a disorder of immune regulation, the identification of activating mutations in the proto-oncogene BRAF-V600E in ~50%-60% of cases and MEK and ERK phosphorylation in 100% of examined cases, has changed the definition of LCH to a dendritic cell neoplasm with a strong...

Topics

Clinical Trials as Topic
Erdheim-Chester Disease
Histiocytosis, Langerhans-Cell
Humans
Imatinib Mesylate
Indoles
Inflammation
MAP Kinase Kinase 1
MAP Kinase Signaling System
Mutation
Phosphorylation
Prospective Studies
Proto-Oncogene Mas
Proto-Oncogene Proteins B-raf
Recurrence
Risk
Sulfonamides
Vemurafenib

Source

Open in PubMed

Identifiers

PMID: 26637773
DOI: 10.1182/asheducation-2015.1.565

Genes

BRAF
ARAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics